CNRS Technologies

Find the best CNRS technologies to boost your innovative project.

Newest patents

You are a research scientist?

We can guide you through the whole technology transfer process.

See all our services

You are a corporate player?

Thanks to our expertise, our network and our know-how of the innovation ecosystem, we support you throughout your project.

Contact us

Follow our news and upcoming events

Discover CNRS technologies

Meet our team

Close

miRNA as new targets for the treatment of respiratory diseases

Reference

02884-01

Patents status

French patent application FR0903723 filed on July 29th, 2009 entitled “Utilisation de microARN pour le traitement de pathologies respiratoires chroniques”

Inventors

Brice MARCET
Pascal BARBRY
Rainer WALDMANN
Bernard MARI
Christelle CORAUX

commercial status

Exclusive or non-exclusive licenses, Collaborative agreement

Laboratory

Institut de Pharmacologie Moléculaire et Cellulaire, a CNRS-Université de Nice laboratory (UMR 6097) in Nice, France.

Description

CONTEXT

Multiciliated cells lining the surface of some vertebrate epithelia are essential for various physiological processes, such as airway cleansing. In many respiratory diseases, among which asthma cystic fibrosis and chronic obstructive pulmonary disease, these cells lose their cilia and cannot evacuate mucus and noxious particles anymore. It is thought that restoring this physiological feature may be of great help in the treatment of respiratory diseases, but until recently, little was known on the molecular pathway of multicilogenesis. 

TECHNICAL DESCRIPTION

Dr Marcet’s team has described new microRNAs specifically expressed in multiciliated cells and implicated in the biosynthesis of these particular structures. When administered to cultured cells, the miR, or their antago-miR, modulate the expression of a panel of genes and are able to induce or block the formation of motile cilia.
In particular, miR449 has been shown to be strongly accumulated in human airway epithelium and Xenopus laevis embryonic epidermis, where it promotes multiciliogenesis and centriole multiplication by directly repressing the Delta/Notch pathway.

HAECs (n=6 donors) were chronically treated with anti-miR-449a/b or control antagomiR (20 nM) during the time of differentiation, typically for 21 days at an air_liquid interface. (a) The relative rate of multiciliated cells was defined as the ratio of the number of β4-tubulin-positive cells to the number of nuclei (20 fields per filter, and 3 inserts per donor, n=6 donors). The histogram indicates the relative rate of multiciliated cells per field in each experimental condition, with the control set to 1. Data are means ± s.d. from six donors (***, P <0:001, Student’s t -test). (b) Real-time RT-PCR experiments indicate that antagomiR-449a/b inhibits miR-449a and miR-449b expression and has no effect on the unrelated microRNA miR-21.
Data are means± s.d.  from six donors (ns, not significant, **, P <0:01, ***, P <0:001, Student’s t -test).

One aspect of the invention consists in the use of these miRNA for the treatment of multiciliated cells disorders. The second aspect of this invention consists in the detection of the level of these miRNA in respiratory epithelia to determine their level of distress.

INDUSTRIAL APPLICATIONS

  • Pharmaceutical compositions for the treatment of respiratory diseases: asthma, COPD, cystic fibrosis, flu, etc…
  • Diagnostic of multiciliated cells distress in respiratory diseases, follow-up of treatment.

BENEFITS

This invention consists in new targets for the treatment of respiratory diseases which enable restoration of a functional respiratory epithelium, and provide means to monitor the state of health of multiciliated epithelia. MicroRNA and their antago-miR are short ribonuceic acid molecules which have proven to be more stable and less fragile than longer RNA or DNA molecules used in genetic therapy. The feasability of their administration by inhalation is very likely.

DEVELOPMENT STAGE

The in vitro proof-of concept has been obtained on cell lines and nasal mucous tissue for several miRNA. Validation is ongoing on mouse models of asthma.

PUBLICATIONS

MicroRNA-based silencing of Delta/Notch signaling promotes multiple cilia formation. Marcet B, Chevalier B, Coraux C, Kodjabachian L, Barbry P. Cell Cycle. 2011 Sep 1;10(17):2858-64. Epub 2011 Sep 1. Review.

Control of vertebrate multiciliogenesis by miR-449 through direct repression of the Delta/Notch pathway. Marcet B, Chevalier B, Luxardi G, Coraux C, Zaragosi LE, Cibois M, Robbe-Sermesant K, Jolly T, Cardinaud B, Moreilhon C, Giovannini-Chami L, Nawrocki-Raby B, Birembaut P, Waldmann R, Kodjabachian L, Barbry P. Nat Cell Biol. 2011 Jun;13(6):693-9. Epub 2011 May 22. Erratum in: Nat Cell Biol. 2011 Oct;13(10):1280.

For further information, please contact us (Ref 02884-01)


Need further information ?

Contact us
Close

Contact us

  • This field is for validation purposes and should be left unchanged.
Close

Newest patents